Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial (ALLHAT) Investigators
Paul K. Whelton, M.D., M.Sc., Principal Investigator
Gail T. Louis, R.N., Study Coordinator Funding Agent
National Heart, Lung, and Blood Institute, NIHParticipating Institutions
Tulane University
University of Texas-Houston Description
This National Institutes of Health, National Heart, Lung and Blood Institute-supported community based factorial trial tested (1) the effectiveness of four first-step anti-hypertensive drug regimens (diuretic; beta-blocker; calcium channel blocker; converting enzyme inhibitor) in reducing coronary heart disease (fatal and non-fatal), and (2) the effectiveness of a lipid-lowering regimen to reduce all-cause mortality. The sample size for this trial was approximately 40,000 and the mean duration of follow-up was approximately 6 years (5-7.5 years). Tulane provided regional coordination (one of nine regional coordination centers) through a subcontract with Clinical Trials Center at the University of Texas-Houston. The goal of the subcontract was to support and coordinate recruitment and follow-up, monitoring, and data collection efforts at approximately 100 ALLHAT clinical centers in the Mid-Atlantic and Southeastern states. Current, post-trial work includes data analysis and study dissemination activities. | 
